<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04773717</url>
  </required_header>
  <id_info>
    <org_study_id>BE-2-5</org_study_id>
    <nct_id>NCT04773717</nct_id>
  </id_info>
  <brief_title>The Effect of High Dose Parenteral Ascorbic Acid On Microcirculation In Sepsis</brief_title>
  <official_title>The Effect of High Dose Parenteral Ascorbic Acid On Microcirculation In Sepsis. Randomized Double-Blind Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lithuanian University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lithuanian University of Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of high-dose ascorbic acid on&#xD;
      microcirculation in sepsis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients with septic shock were enrolled within 24 hours following admission to the&#xD;
      Central Department of Intensive Care in Lithuanian University of Health Sciences Hospital&#xD;
      Kaunas Clinics.&#xD;
&#xD;
      Participants were randomly assigned to a placebo or ascorbic acid group in a 1:1 ratio. They&#xD;
      were resuscitated according to Surviving Sepsis Campaign Guidelines. Additionally, they&#xD;
      received an intravenous infusion of ascorbic acid either placebo. The dose of ascorbic acid&#xD;
      was 200mg/kg/24h divided into four equal parts for 96 hours. Sublingual microcirculatory&#xD;
      measurements were obtained, using an incident dark field (IDF) device.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">January 31, 2021</completion_date>
  <primary_completion_date type="Actual">January 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microvascular flow index (MFI)</measure>
    <time_frame>Baseline, after 0.5, 6, 12, 24, 48, 72 and 96 hours</time_frame>
    <description>Changes in MFI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of perfused small vessels (PPV)</measure>
    <time_frame>Baseline, after 0.5, 6, 12, 24, 48, 72 and 96 hours</time_frame>
    <description>Changes in PPV</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Ascorbic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received a high dose of intravenous ascorbic acid in four equal parts daily for 96 hours.&#xD;
Images of sublingual microcirculation were obtained at a baseline, after 0.5, 6, 12, 24, 48, 72, and 96 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients received placebo solution matching ascorbic acid solution as four equal parts daily for 96 hours. Images of sublingual microcirculation were obtained at a baseline, after 0.5, 6, 12, 24, 48, 72, and 96 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic acid</intervention_name>
    <description>200mg/kg/24h in four equal parts</description>
    <arm_group_label>Ascorbic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The same regimen as ascorbic acid.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with sepsis or septic shock within the first 24 hours after ICU admission.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years,&#xD;
&#xD;
          -  Pregnancy,&#xD;
&#xD;
          -  Advanced malignancy,&#xD;
&#xD;
          -  History of kidney stone, glucose-6-phosphate deficiency, hemochromatosis, or solid&#xD;
             organ transplantation,&#xD;
&#xD;
          -  Oral mucosal inflammation or injury or technical difficulties in obtaining sublingual&#xD;
             images.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lithuanian University of Health Sciences Hospital Kaunas Clinics</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lithuania</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 21, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>February 28, 2021</last_update_submitted>
  <last_update_submitted_qc>February 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lithuanian University of Health Sciences</investigator_affiliation>
    <investigator_full_name>Andrius Pranskunas</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Microcirculation</keyword>
  <keyword>Ascorbic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

